Bio-techne

Bio-techne

TECH
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

TECH · Stock Price

USD 50.91+0.97 (+1.94%)
Market Cap: $7.6B

Historical price data

Market Cap: $7.6BPatents: 12Founded: 1976Employees: 3,000-4,000HQ: Minneapolis, United States

Overview

Bio-Techne's mission is to provide the critical tools and technologies that enable scientific discovery and clinical validation across the life sciences continuum. The company has achieved a leadership position in protein sciences and spatial biology through a disciplined strategy of organic innovation and strategic acquisitions, building a portfolio of trusted brands like R&D Systems, Novus Biologicals, and ProteinSimple. Its strategy focuses on leveraging its core reagent expertise to drive growth in high-value adjacencies, particularly in spatial biology, multi-omics, and clinical diagnostics, serving a stable and diverse global customer base.

OncologyEndocrinologyNeuroscienceImmunology

Technology Platform

An integrated ecosystem of technologies spanning core protein/antibody reagents, automated protein analysis instruments, and a leading spatial biology platform for in-situ hybridization and sequencing-based spatial transcriptomics, enabling multi-omics research and clinical diagnostics.

FDA Approved Drugs

7
IBTROZINDAJun 11, 2025
AVZIVIBLADec 6, 2023
METHOCARBAMOLANDAJun 12, 2023

Opportunities

The primary growth opportunity lies in the rapidly expanding spatial biology market, where Bio-Techne's AtoMx platform is well-positioned.
Additional opportunities include increased penetration of automated protein analysis in biopharma development and leveraging spatial technologies for companion diagnostic partnerships.
The stable, diversified customer base across research and diagnostics provides a resilient foundation for capturing these growth vectors.

Risk Factors

Key risks include sensitivity to reductions in global life science R&D funding, intense competition in high-growth areas like spatial biology, and execution risks associated with integrating acquired technologies.
Regulatory hurdles in the diagnostics segment and foreign exchange volatility also pose material challenges.

Competitive Landscape

Bio-Techne faces competition from large, diversified players like Thermo Fisher in reagents, and specialized rivals like 10x Genomics, Bruker (NanoString), and Vizgen in the high-growth spatial biology arena. Its competitive moat is built on brand reputation for quality, an integrated portfolio that creates workflow stickiness, and deep scientific expertise.

Company Timeline

1976Founded

Founded in Minneapolis, United States

2023FDA Approval

FDA Approval: AVZIVI

2023FDA Approval

FDA Approval: METHOCARBAMOL

2025FDA Approval

FDA Approval: IBTROZI